Drug intelligence / Profile preview

RSVpreF + qIRV

Development stage: Unknown
Lead developer: Pfizer
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RSVpreF + qIRV is an mRNA-based combination vaccine candidate that combines Pfizer's RSVpreF (respiratory syncytial virus prefusion F protein) vaccine with their quadrivalent modRNA-based influenza vaccine candidate (qIRV). This combination approach aims to protect against both respiratory syncytial virus (RSV) and influenza with a single vaccination, potentially simplifying immunization practices and improving vaccine uptake for both diseases.

Targets

HMPV F (Human metapneumovirus fusion protein)Quadrivalent influenza virus hemagglutinin and neuraminidase antigens

Beyond the preview

Go deeper on RSVpreF + qIRV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSVpreF + qIRV.

Explore the full profile